XRCC2 and glioblastoma: Overexpression of X-ray repair cross-complementing group 2(XRCC2) is a hallmark of neoplastic cells and especially in glioblastoma tumor cells leads to resistance against anticancer drugs Temozolomide (TMZ) (51).